SARS-CoV-2 Main Protease (Mpro) H164N Mutant in Complex with Inhibitor GC376

SARS-CoV-2 Main Protease (Mpro) H164N Mutant in Complex with Inhibitor GC376 Descriptor: (1S,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid, 3C-like proteinase nsp5 Authors: Lewandowski, E.M, Butler, S.G, Hu, Y, Tan, H, Wang, J, Chen, Y. Deposit date: 2022-06-17 Release date: 2022-07-13 Last modified: 2024-10-30 Method: X-RAY DIFFRACTION (2.03 Å) Cite: Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir. Acs Cent.Sci., 9, 2023本数据集为严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）主蛋白酶（Main Protease, Mpro）H164N突变体与抑制剂GC376的复合物相关数据；配体描述为：(1S,2S)-2-({N-[(苄氧基)羰基]-L-亮氨酰}氨基)-1-羟基-3-[(3S)-2-氧代吡咯烷-3-基]丙烷-1-磺酸，靶标为3C样蛋白酶nsp5（3C-like proteinase nsp5）。作者：Lewandowski, E.M、Butler, S.G、Hu, Y、Tan, H、Wang, J、Chen, Y。提交日期：2022-06-17，发布日期：2022-07-13，最后修改日期：2024-10-30。实验方法：X射线衍射（2.03 Å）。引用文献：《SARS-CoV-2主蛋白酶的天然突变可赋予奈玛特韦耐药性》，发表于Acs Cent.Sci., 9, 2023。